Tony Pantalleresco Radio Show Of the Month November 9 2012

 Show Topics


  • Pine Needle– Pine and White Oak Bark
  • Lysine Uses and Pharmacology
  • Hair formula pine-bamboo-apricot
  • Bayer to acquire Utah vitamin maker Schiff for $1.1 billion


Pine Needle–

A method for treating a disease, comprising the administration of a therapeutically effective amount of the composition of claim 8; wherein the disease is selected from the group consisting of hypertension, diabetes, coronary heart disease, angina pectoris, arrhythmia, myocarditis, hyperlipidemia, high blood viscosity, high blood aggregation, cerebral infarction, arterial sclerosis, cerebral arteriosclerosis, and senile dementia.– The extract of pine needle of this invention is compatible with other drags in treating the above or other diseases. For example, it can not only lower blood pressure, blood-lipid, blood sugar, blood viscosity and the aggregation rate of platelet, but also regulate calcium metabolism when used together with calcium supplements.— Take pine needle as a raw material. The pine needle can be processed in whole or be cut into segments or triturated into powder before processing. It is preferred to cut pine needle into segments before treatment. Add excess water into pine needle. The water added is at least 4 times (by weight), preferably 8-9 times, of the pine needle. The mixture is heated to boiling for extracting. The time period for boiling is 1-2 hours and preferably 1.5h[U2] . The mixture is filtered after extracting and then condensed to give a concentrated solution in dark brown[U3] – The residue from the filtration may be extracted for second time by being added with water and boiling. The added water is at least 3 times by weight of the residue, while 6-7 times is preferred. The time for boiling is 0.5-1.5 hours, preferably 1h. After the filtration of second time, The filtrate of the second time can be combined with the filtrate of the first time and then they can be condensed together to get the condensed solution.

Pine and White Oak Bark

A method for treating diseases, comprising the administration of therapeutically effective amount of the extract of pine needle of this invention to patients. These diseases include: hypertension, diabetes, CHD, angina pectoris, arrhythmia, myocarditis, hyperlipemia, high blood viscosity, high blood aggregation, cerebral infarction, senile dementia, arterial sclerosis, and sudden deafness.—A method for extraction and isolation of tannic and gallic acid from the bark of oak and pine trees respectively; said method comprising the steps of: a) carefully screening the oak bark and pine tree bark which may be fresh, wet or dry, and may be comprised of inner or outer said bark; b) said bark is selected and thoroughly washed at room temperature; c) said bark is then added to previously boiled water in a reaction vessel, the preferred extraction during this process may occur with or without agitation, preferably, the process provides for stirring said preferred extraction in order to recover the end product at a faster rate; d) said extraction process provides for a resultant stream of one pound of said bark which has been previously added to three gallons of boiled water in a range of 75-95 degrees Celsius, thus said extraction process is a batch operation either with or without agitation;


Hair formula pine-bamboo-apricot

A pine extract in combination of a bamboo extract and/or a Japanese apricot extract effectively promotes the growth and regeneration of hair for human and animals. Administration of these compounds leads to no substantial side effects. The external-usable hair restorer containing these compounds is also effective in the prevention of alopecias, as well as in the protection of falling out of hair, dandruff, and itching of the scalp. These properties render these compounds useful in hair restorers for human and animals.

Making a extract would be to take either water-alcohol-or fat and merging these materials together—in this case you would take equal  parts of bamboo and pine and apricot boil this to ¾ down from where you start—-and when done allow to cool

Then strain and apply to the topical part of the head and massage daily


Bayer to acquire Utah vitamin maker Schiff for $1.1 billion

Purchase • Acquisition is 3rd big transaction involving a state company in 2012.

Bayer AG agreed to buy Utah’s Schiff Nutrition International Inc. for $1.1 billion to add a faster- growing vitamins and nutritional supplements business to the German drugmaker’s consumer-health unit.–The deal marks the third billion-dollar acquisition of a state-based company this year. Earlier, Blackstone agreed to buy Vivint for $2 billion, and Permira Funds said it would buy for $1.6 billion.—-Schiff investors will receive $34 a share in cash, Bayer said in a statement Tuesday. The price is 47 percent above Schiff’s closing level Oct. 26, the most recent day of stock trading in the U.S. Bayer also said its third-quarter profit rose 2.2 percent.–“Schiff has a 75 year heritage of providing consumers with quality nutritional products,” Tarang Amin, president and CEO of Schiff, said in a prepared statement. “We are focused on building premium brands and leading innovation. We believe Bayer is well positioned to take our leading brands to the next level.”—Schiff sells its brands primarily through retail outlets, with Costco and Walmart its largest customers.–The sale illustrates how mainstream food and pharmaceutical companies are moving into nutritional supplement and health food areas traditionally the venue of smaller companies, including many in Utah.—Bayer will strengthen its U.S. consumer-health unit with the Salt Lake City-based business. Signed about six weeks after Bayer agreed to buy Teva Pharmaceutical Industries Ltd.’s animal-health business, the deal fits Bayer’s strategy of building its life sciences unit with small- and midsized acquisitions, CEO Marijn Dekkers said.–“These are two of the areas that we are very committed to growing, both organically and with these bolt-on acquisitions,” Dekkers said in a Bloomberg Television interview.–Schiff sales in the year ended May 31 totaled $259 million. The company said last month that sales this fiscal year would increase by 43 percent to 46 percent after its acquisition in April of Airborne, the cult cold-prevention remedy touted by Oprah Winfrey and originally marketed to airline passengers.—Schiff also makes Tiger’s Milk nutrition bars, Omega-3 product MegaRed and Move Free, a pill for joints. Schiff, which during its 2011 fiscal year generated revenue of $214 million, has 414 employees. —The Utah company won’t seek a competing offer, although it has the option to review unsolicited bids until Nov. 28, Schiff said in a regulatory filing. Chairman Eric Weider’s company Weider Health and Fitness, which owns a controlling stake in Schiff, agreed to the deal, according to the filing.–“Nutritionals are a reasonably fast-growing area,” said Alistair Campbell, an analyst at Berenberg Bank in London who recommends buying Bayer stock. “It broadens their product line.”

The deal is expected to close by the end of 2012. —Schiff declined 0.4 percent, to close at $23.19 on the New York Stock Exchange Oct. 26. Trading was closed Monday and Tuesday in the U.S. because of Hurricane Sandy. TPG, the Fort Worth, Texas-based buyout firm, owns 34 percent of Schiff’s shares, according to data compiled by Bloomberg.  -In 2010, Schiff sold 25 percent of its shares to the Texas private-equity firm, TPG Growth. Schiff exchanged 7.48 million shares from Weider Health and Fitness, its majority owner, for equity in the Texas company in a deal valued at $48.8 million, according to a filing with the Securities and Exchange Commission.

The purchase announed Tuesday, including net debt, values Schiff at 17.8 times this year’s estimated earnings before interest, tax, depreciation and amortization. Buyers have paid a median 16.9 times profit for acquisitions of vitamin companies over the past five years, according to data compiled by Bloomberg.  -The purchase price is based on 31.1 million shares outstanding. Bayer also is assuming $122 million in net debt.–Growth in the health and crop-chemical business helped push earnings up in the third quarter, Bayer said in a separate statement. Earnings before interest, taxes, depreciation, amortization and special items increased to 1.85 billion euros ($2.39 billion) from 1.81 billion euros a year earlier, Bayer said.